zijian-li1228 commented 2 years ago

Discussion worksheet

The paper you are working on?

Gaebler et al., 2021

Main Research Question?

How does antibody against SARS-CoV-2 evolve wrt anti-RBD level, memory B cell population and mutations in IGHV&IGLV post COVID infection, and how do they affect neutralizing activity in the long term?

Methods & Data

anti-RBD level and neutralizing activity decrease 6 months post COVID infection (ELISA)
percentage of RBD-binding memory B cells increased marginally (FACS)
mutations in IGH and IGL increased significantly after 6 mo and clonal composition of memory compartment changed significantly (cDNA sequencing)
EC50 improve after 6 mo which could be correlated to RBD mutations critical for the binding of class2 and 3 antibodies (ELISA)
memory b cells that evolved during the observation period express antibodies with increased neutralizing potency and breadth (pseudotyped virus neutralization assay)
antigen persistence in ACE2 expressing epithelial cells could contribute to B cell and antibody changes (IF)

Authors' interpretation

I agree with the authors' interpretation that individuals infected with SARS-CoV-2 could have a faster immune response upon re-exposure. However, I'm wondering if greater antibody potency=quicker inflammation resolution=faster recovery necessarily?

Enhancement or next experiment?

increase n, longer followup

Confusion? Terms you don't understand?

No at this point

Have your own opinions or critiques

I'm wondering if this study has any implication for predicting how the next strain of SARS-CoV-2? Also would the antibodies evolve the same way for patients recovering from COVID vs vaccination?

I hereby confirm that I have:

[ ] I am still working on the worksheet
[x] I have finished the worksheet
[x] I have gone through the papers
[x] Check your peer if they have similar ideas. If it is, plz add their issue number to your comments.

gmhhope commented 2 years ago

Effects of vaccine, infection/reinfection with new strains

I'm wondering if this study has any implication for predicting how the next strain of SARS-CoV-2? Also would the antibodies evolve the same way for patients recovering from COVID vs vaccination?

Very good! These are by far the best forward-looking question! If this paper published in 2022, this will be certainly a concern to address in this paper.

Connections with antibody-mediated inflammatory responses

However, I'm wondering if greater antibody potency=quicker inflammation resolution=faster recovery necessarily?

That is also an excellent question especially considering the finding that you just presented last week : ) Fucosylation?